Will Amphastar Pharmaceuticals stock go up?

According to Danelfin AI, Amphastar Pharmaceuticals has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.50%) is +7.68% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Amphastar Pharmaceuticals stock?

The Amphastar Pharmaceuticals target price is $19.66 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Amphastar Pharmaceuticals stock right now?

Amphastar Pharmaceuticals has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (58.50%) is +7.68% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Amphastar Pharmaceuticals stock is a good buy .

Is Amphastar Pharmaceuticals undervalued right now?

Based on analysts, the average price target downside for Amphastar Pharmaceuticals is 0.00% (1Y). According to Danelfin AI, Amphastar Pharmaceuticals has today an AI Score of 7/10 (Buy Rating).

What was the price range of Amphastar Pharmaceuticals stock over the past 12 months?

The Amphastar Pharmaceuticals stock price range over the past 12 months has been $16.87 - $30.81.

What is going on with Amphastar Pharmaceuticals stock in the last 3 months?

The Amphastar Pharmaceuticals stock performance in the last quarter has been -2.86%.

Does Amphastar Pharmaceuticals offer dividend payments?

No, Amphastar Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals's market cap is $865.99M, as of 2026-07-03 08:00.

Amphastar Pharmaceuticals Inc (AMPH) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

AMPH AI-Powered Stock Analysis

AI Score Explanation

AI Score

Buy

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Amphastar Pharmaceuticals Inc today receives an AI Score of 7/10, which translates to a Buy rating. The stock has a 59% probability of outperforming the market in the next 3 months, which is 8% higher than the average probability of any stock (51%). Key positive contributors include the long-tail fundamentals impact (+2.86%), the Pharmaceuticals industry (+0.84%), and technicals impact (+0.63%). Additionally, a low forward P/E ratio in the bottom 10% adds +0.34%, while strong cash per share in the top 20% contributes +0.34%. On the negative side, the 6-month alpha in the bottom 20% detracts -0.43%, and the 120-day chart pattern reduces probability by -0.25%. Notable data points include a year-to-date performance in the bottom 30% (-26.6%) yet it still positively influences the probability (+0.46%), suggesting the weakness may be priced in. Operating cash flow in the top 40% ($47.84M) and tangible equity in the top 50% ($213.77M) reflect solid fundamentals. However, the negative alpha over 6 months and 1 year (both in bottom deciles) indicate recent underperformance. Overall, the stock’s attractive valuation (low forward P/E) and strong cash position outweigh the technical weakness, supporting the Buy rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+4.07%
How the stock is priced relative to its fundamentals
Momentum+2.24%
Direction and strength of recent price movements
Sentiment+0.76%
How analysts and the market view the stock
Earnings Quality+0.38%
Stability and reliability of reported earnings
Size & Liquidity+0.22%
Company size and trading liquidity

AMPH probability advantage of beating the market (3M):

+7.68%

Technical

Amphastar Pharmaceuticals (AMPH) has a Technical Score of 7/10 because, according to only technical analysis, it has a probability advantage of +2.66% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of AMPH (53.39%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
AMPH probability advantage of beating the market (only technical, 3M)+2.66%
AMPH probability of beating the market (3M)53.39%

AMPH probability advantage of beating the market (only technical, 3M): +2.66%

The AI-powered technical analysis of Amphastar Pharmaceuticals (AMPH) is only based on the 29 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of AMPH:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	-2.09%
Technical	Upgrade to Pro to unlock	+1.43%
Technical	Upgrade to Pro to unlock	+0.95%
Technical	Upgrade to Pro to unlock	+0.82%
Technical	Upgrade to Pro to unlock	+0.78%
Technical	Upgrade to Pro to unlock	-0.48%
Technical	Upgrade to Pro to unlock	-0.42%
Technical	Upgrade to Pro to unlock	-0.39%
Technical	Upgrade to Pro to unlock	+0.35%
Technical	Upgrade to Pro to unlock	+0.34%
Technical	Upgrade to Pro to unlock	-0.33%
Technical	Upgrade to Pro to unlock	+0.30%
Technical	Upgrade to Pro to unlock	+0.28%
Technical	Upgrade to Pro to unlock	+0.28%
Technical	Upgrade to Pro to unlock	-0.27%

Rest of Alpha Signals: +1.10%

AMPH probability advantage of beating the market (only technical, 3M)Total:+2.66%
AMPH Technical Score

Significant changes Vs previous day

AMPH Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$19.66
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

AMPH Proven Buy Signal & Price Forecast

This is the price chart for AMPH from January 2, 2026 until today. The chart indicates, in green, the 46 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

AMPH Average Past Performance & Win Rate

Three months after its 420 Buy signals since July 2026, AMPH had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

420 Past AMPH Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+35.12%
Average Alpha				+18.80%
Win Rate (% Positive Perf.)				79.05%
% Positive Alpha				64.03%

AMPH Frequently Asked Questions

Will Amphastar Pharmaceuticals stock go up?
According to Danelfin AI, Amphastar Pharmaceuticals has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (58.50%) is +7.68% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Amphastar Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Amphastar Pharmaceuticals stock right now?
Is Amphastar Pharmaceuticals undervalued right now?
What was the price range of Amphastar Pharmaceuticals stock over the past 12 months?
What is going on with Amphastar Pharmaceuticals stock in the last 3 months?
Does Amphastar Pharmaceuticals offer dividend payments?
What is the current market capitalization of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals Inc Company Profile

Founded in 1996, Amphastar Pharmaceuticals, Inc. is a leading biopharmaceutical company specializing in the research, development, production and marketing of both generic and proprietary injectable, inhalation, and intranasal medications across prominent markets including the United States, China, and France.

The company boasts a broad product portfolio that addresses various medical needs. This includes their nasal spray BAQSIMI utilized for mitigating severe hypoglycemia, as well as Primatene Mist—a readily available epinephrine inhalation solution—designed to alleviate mild symptoms of intermittent asthma. Other offerings include Enoxaparin for preventing deep vein thrombosis; REXTOVY and Naloxone used for treating opioid overdose cases; Glucagon which acts as a handy emergency injection kit; Cortrosyn employed as a diagnostic tool for adrenocortical insufficiency investigation.

Additionally, products like Amphadase—designed to absorb dispersed injected drugs–alongside Lidocaine Jelly—an anesthetic commonly used in urological procedures—demonstrate the company's commitment to patient comfort during treatment. The Phytonadione injection is another critical offering by the firm aimed at ensuring vitamin K1 levels are maintained in newborns. Not to forget their ingenious inventions like morphine injection compatible with patient-controlled analgesia pumps, Lorazepam injections useful during medical procedures and surgeries.

Moreover, the firm also offers solutions such as Neostigmine methylsulfate injection a resort against myasthenia gravis and reversing muscle relaxant effects. Meanwhile, the Isoproterenol hydrochloride injection serves temporarily during heart block episodes with Ganirelix Acetate managing premature luteinizing hormone surges. The company's Regadenoson offering functions as a stress agent for radionuclide myocardial perfusion scanning.

Continuing its pioneering work in the biopharmaceutical field, Amphastar Pharmaceuticals distributes recombinant human insulin APIs alongside porcine insulin API. And its pipeline of developmental pharmaceuticals is brimming with an impressive range of generic as well as biosimilar product contenders like innovative injectable, inhalation, and analytical technologies. They are also developing intranasal epinephrine for treating allergic reactions.

Amphastar Pharmaceuticals has rooted its headquarters amidst the stunning backdrop of Rancho Cucamonga, California, from where it continues its mission to innovate and revolutionize healthcare solutions.

Sector:
Country:United States
Industry:
Address:11570 6th St, Rancho Cucamonga
Employees:1,976
Website:amphastar.com

Pros

Diversified product portfolio across dosage forms

Vertical integration in active pharmaceutical ingredient production

Pipeline of complex generic and biosimilar candidates

High regulatory barriers to entry for complex injectables

Established distribution network for hospital and clinic sales

Cons

Generic drug market price erosion pressure

Extended regulatory approval timelines for novel products

Dependency on specific raw material suppliers

Litigation expenses from patent infringement challenges

Capital expenditure requirements for manufacturing upgrades

AMPH Stock AI Analysis